Ads
related to: eli lilly- Press Releases
Find Press Releases
and News for Lilly.
- Lilly Recognitions
Leaders in D&I, R&D, and
Social Impact & Employee Benefits
- About Lilly
Find How Lilly's Purpose Has Never
Been More Important.
- Our Impact
Learn About How We Responsibly
Grow Our Business.
- Press Releases
Search results
Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030,...
Business Insider via Yahoo Finance· 2 days agoZepbound is Eli Lilly's new weight-loss drug.Brendan McDermid/Reuters The anti-obesity drug market...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 21 hours agoEli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their...
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
The Motley Fool via AOL· 21 hours agoOther companies are looking to challenge the Denmark-based drugmaker. Its longtime rival in the diabetes market, Eli Lilly (NYSE: LLY), recently launched ...
Eli Lilly adds ALS drug prospect with QurAlis deal
BioPharma Dive via Yahoo Finance· 1 day agoThe alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to...
Is Eli Lilly And Co (NYSE:LLY) the Best Weight Loss Stock to Buy in 2024?
Insider Monkey via Yahoo Finance· 4 days agoWe recently published a list of Jim Cramer’s Top 10 Stock Picks for June. Since Eli Lilly And Co...
The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
Zacks via Yahoo Finance· 21 hours agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
...Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says...
Benzinga· 15 hours agoStructure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290,...
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate | The Motley Fool
The Motley Fool· 21 hours agoInvestors interested in the pharmaceutical industry are currently excited about the anti-obesity...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
The Motley Fool via AOL· 21 hours agoEli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue ...
The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
Zacks· 1 day agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli
Ad
related to: eli lilly